Project Grant R01CA308406
Award Date 7/1/26
Completion Date 6/30/31
Dollars Obligated $710K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Nashville, TN 37203, USA
Similar Awards
- Federal Grant Award Summary Award Details: The National Cancer Institute, under the Cancer Detection and Diagnosis Research Program (CFDA 93.394), awarded Vanderbilt University a Project Grant of $2,958,465 on September 19, 2025, for a four-year project period extending through August 31, 2029. The project aims to develop an innovative diagnostic tool to improve detection of urothelial carcinoma in situ (CIS) during bladder cancer surveillance. Products and Services: Vanderbilt University is...
- Federal Project Grant Award Summary Vanderbilt University received a $150,104 Project Grant from the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398) on December 17, 2025, with a completion date of December 31, 2026. The award supports research focused on developing small molecule inhibitors targeting the interaction between xeroderma pigmentosum complementation group A (XPA) and replication protein A (RPA)—two critical proteins in the nucleotide excision repair...
- Federal Project Grant Award Summary The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research a $745,471 Project Grant effective July 1, 2026, through June 30, 2031, under the Cancer Treatment Research program (CFDA 93.395). This research initiative, titled "Hematopoietic Stem Cell Encoded Anti-Tumor Immunity: Mechanisms and Function," focuses on elucidating the mechanisms of action underlying Bacillus Calmette-Guerin (BCG) immunotherapy for non-muscle...
- Grant Award Summary Vanderbilt University Medical Center received a $695,884 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) effective June 23, 2026, through May 31, 2031. The award supports research investigating selective loss of Human Leukocyte Antigen (HLA) gene products in triple-negative breast cancer (TNBC) immunobiology and their implications for immune checkpoint inhibition (ICI) resistance. The research team will develop and...
- Federal Project Grant Award Summary Vanderbilt University's Sponsored Programs Administration received a $149,190 Project Grant award from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398) to support biomedical research training in cancer biology. The award, obligated on December 30, 2025, with an ultimate completion date of June 30, 2028, funds research characterizing the role of cancer-associated U2 Small Nuclear RNA Auxiliary Factor (U2AF)...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Columbia University's Health Sciences Division a $683,970 Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective April 1, 2026, through March 31, 2031. This award supports research investigating tumor-penetrating stromal modification strategies targeting αvβ5 integrin in pancreatic ductal adenocarcinoma (PDAC). The project examines how the IRGD tumor-penetrating peptide inhibits αvβ5-mediated...
- Federal Grant Award Summary The National Cancer Institute awarded The Institute For Cancer Research a $186,000 Project Grant under the Cancer Treatment Research program (CFDA 93.395) on June 23, 2025, with a completion date of May 31, 2027. The award supports pilot and feasibility studies for NN-01-195, a novel tumor-targeted Aurora-A kinase (AURKA) inhibitor developed through a drug conjugate approach. The research involves preclinical evaluation of this chimeric compound, which fuses an...
- Federal Project Grant Award Summary The University of Massachusetts received a $706,479 Project Grant from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) awarded on June 11, 2026, with completion expected by May 31, 2031. This award supports the development and validation of whole bladder urothelial resurfacing (WBUR) using irreversible electroporation (IRE) technology as an adjuvant therapy for non-muscle invasive bladder cancer...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded The Institute For Cancer Research a $766,439 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) effective April 1, 2026, through March 31, 2031. This research initiative addresses the clinical challenge of bladder cancer patients avoiding radical cystectomy by investigating intratumor heterogeneity as a predictor of clinical outcomes. The project delivers two primary research...
- Federal Grant Award Summary The National Cancer Institute awarded the University of Kansas Medical Center Research Institute, Inc. a $398,544 Project Grant (CFDA 93.395: Cancer Treatment Research) effective April 8, 2026, through March 31, 2028, to conduct pre-clinical evaluation of PRT3789, a highly selective SMARCA2 degrader, for treating therapy-resistant triple-negative breast cancer (TNBC). The project addresses a critical clinical gap: patients with residual disease following neoadjuvant...